Singapore, May 25 -- Lotus Pharmaceutical, a global pharmaceutical company headquartered in Taiwan, has entered into an agreement with OM Pharma, a global biopharmaceutical company headquartered in Geneva, Switzerland to acquire the assets of a specialty biopharmaceutical product for the prevention of recurrent urinary tract infections in South Korea including the transfer of marketing authorisations, trademarks, finished product inventory, and other relevant intellectual property rights.

The acquisition is expected to strengthen Lotus' specialty portfolio and further expand its presence in South Korea, one of the company's key Asian markets.

The acquired product has an established clinical profile and long-standing market presence, wit...